AngioDynamics guides Q2 cash ~$28-30M; results due Jan 5, 2023

ANGIODYNAMICS INC

Expected cash at Nov 30, 2022 (Q2 FY2023 end): $28-30 million.
Net cash increase of ~$3.5-5.5M from Q1 FY2023 end.
Cash guidance excludes $4.2M CARES Act receivable.
Q2 FY2023 earnings scheduled for release on or around Jan 5, 2023.

item 2.02 item 7.01 item 9.01

ANGIODYNAMICS INC filing history →

Source: SEC EDGAR

accession 0001140361-22-043590

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.